104 related articles for article (PubMed ID: 38768457)
1. Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance : An Analysis From a Population-Based Screening Study.
Sverrisdottir I; Thorsteinsdottir S; Rognvaldsson S; Aspelund T; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Thorsteinsdóttir I; Sveinsdottir SV; Palmason R; Olafsson I; Sigurdsson F; Thordardóttir AR; Eythorsson E; Jonsson A; Palsson R; Indridason OS; Gislason GK; Olafsson A; Sigurdsson J; Steingrímsdóttir H; Einarsson Long T; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY; Love TJ
Ann Intern Med; 2024 Jun; 177(6):711-718. PubMed ID: 38768457
[TBL] [Abstract][Full Text] [Related]
2. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
3. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
Blood Cancer J; 2021 May; 11(5):94. PubMed ID: 34001889
[TBL] [Abstract][Full Text] [Related]
4. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.
Rognvaldsson S; Eythorsson E; Thorsteinsdottir S; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Thorsteinsdóttir I; Olafsson I; Runolfsdottir HL; Helgason D; Emilsdottir AR; Agustsson AS; Bjornsson AH; Kristjansdottir G; Thordardottir AR; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Steingrimsdottir H; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Palsson R; Love TJ; Kristinsson SY
Blood Cancer J; 2021 Dec; 11(12):191. PubMed ID: 34853309
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.
Baldursdóttir TR; Löve ÞJ; Gíslason GK; Björkholm M; Mellqvist UH; Lund SH; Blimark CH; Turesson I; Hultcrantz M; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Mar; 106(3):380-388. PubMed ID: 33295006
[TBL] [Abstract][Full Text] [Related]
7. History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
Lindqvist EK; Landgren O; Lund SH; Turesson I; Hultcrantz M; Goldin L; Björkholm M; Kristinsson SY
Ann Hematol; 2017 Feb; 96(2):261-269. PubMed ID: 27807648
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
[TBL] [Abstract][Full Text] [Related]
10. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
[TBL] [Abstract][Full Text] [Related]
11. Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden.
Rögnvaldsson S; Thorsteinsdóttir S; Syriopoulou E; Sverrisdottir I; Turesson I; Eythorsson E; Oskarsson JT; Long TE; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Aspelund T; Gislason GK; Olafsson A; Sigurdsson JK; Hultcrantz M; Durie BGM; Harding S; Bjorkholm M; Landgren O; Love TJ; Kristinsson SY
Haematologica; 2024 Jan; ():. PubMed ID: 38205512
[TBL] [Abstract][Full Text] [Related]
12. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.
McShane CM; Murray LJ; Landgren O; O'Rorke MA; Korde N; Kunzmann AT; Ismail MR; Anderson LA
Cancer Epidemiol Biomarkers Prev; 2014 Feb; 23(2):332-42. PubMed ID: 24451437
[TBL] [Abstract][Full Text] [Related]
13. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
14. Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study.
Rögnvaldsson S; Aspelund T; Thorsteinsdóttir S; Turesson I; Björkholm M; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Jul; 107(1):137-144. PubMed ID: 33840154
[TBL] [Abstract][Full Text] [Related]
15. Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.
Sigurbergsdóttir AÝ; Love TJ; Kristinsson SY
Front Immunol; 2022; 13():876271. PubMed ID: 35572590
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
17. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D and monoclonal gammopathy of undetermined significance (MGUS) among U.S. Black women.
Ruiz Lopez JN; McNeil GE; Zirpoli G; Palmer JR; Kataria Y; Bertrand KA
Cancer Causes Control; 2024 Feb; 35(2):277-279. PubMed ID: 37707565
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review.
Castaneda-Avila MA; Ulbricht CM; Epstein MM
Ann Hematol; 2021 Apr; 100(4):855-863. PubMed ID: 33416902
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
